Columbia, Maryland, April 4, 2018 – Welldoc®, a leading digital therapeutics company, announced today that its executives and digital health, diabetes and healthcare industry thought leaders will speak and/or participate in panel discussions at prominent diabetes and healthcare conferences this Spring. The list of events is as follows:
Johns Hopkins Clinical Continuing Education Series
April 4, 2018, Johns Hopkins University, Baltimore, MD
Janice MacLeod, MA, RDN, LDN, CDE, will present “The Brave New World of Diabetes Education: Remodeling Your Practice in an Evolving Healthcare Environment” at 2:00 p.m. ET.
Florida Health Care Coalition 25th Annual Conference
April 10, 2018, Rosen Centre Hotel, Orlando, FL
Welldoc Chief Strategy Officer Anand K. Iyer, PhD, MBA, will present “Digital Therapeutics: Hitting the Sweet Spot in Diabetes – Engaging Patients, Delivering Outcomes” at 10:45 a.m. ET.
2018 BioHealth Capital Region Forum
April 23 – 24, 2018, MedImmune, Gaithersburg, MD
Welldoc Chief Executive Officer Kevin McRaith will present on April 23.
Digital Therapeutics in the NHS Summit
April 24, 2018, Carisbrooke Hall, London, UK
Dr. Iyer will participate in the panel discussion “Interrogating the Evidence.”
2018 Health Datapalooza
April 26 – 27, 2018, Washington Hilton, Washington, D.C.
Ms. MacLeod will present on April 27 at 9:15 a.m. ET.
MBGH 38th Annual Conference
May 2 – 3, 2018, The Mid-America Club, Chicago, IL
Welldoc Chief Revenue Officer Laurel Pickering, MPH, will present “Digital Health: A tool to engage people and lower cost” on May 2 at 1:15 p.m. CT.
Memphis Business Group on Health
May 2, 2018, Memphis Business Group on Health, Memphis, TN
Ms. MacLeod will present at 8:30 a.m. CT.
Employers’ Health Coalition
May 16, 2018, Kent State University, Stark Campus, Canton, OH
Ms. Pickering will present “Digital Health: A tool to engage people and lower cost.”
Diabetes Technology Society Digital Diabetes Congress
May 22 – 23, 2018, Marines’ Memorial Club & Hotel, San Francisco, CA
Dr. Iyer will participate in the panel discussion “Regulatory Aspects of Digital Health” on May 22 at 2:05 p.m. PT.
BlueStar®, powered by Welldoc®, is an FDA-cleared, proven digital therapeutic that is an in-app coach engaging people with type 2 diabetes. It delivers personalized, real-time feedback, as well as diabetes educational tools that are actionable and individualized. Specifically, Welldoc has developed more than 30 peer-reviewed publications and presentations on BlueStar, including two randomized, controlled clinical trials. Our clinical evidence shows a 1.7 to 2.0-point mean A1C reduction for adults living with type 2 diabetes who used BlueStar. In November 2017, the IQVIA Institute for Human Data Science (formerly Quintiles/IMS) named BlueStar the “top app” in clinical diabetes treatment. BlueStar delivers an estimated average cost savings of $254-$271 per user per month, proven clinical outcomes and a net promoter member satisfaction score of 70. For more information on BlueStar, visit: www2.bluestardiabetes.com.
This year, Samsung Electronics America, Inc. and Welldoc announced that Samsung Health users now have access to a new consumer version of Welldoc’s digital platform known as the Diabetes Wellness Program (DWP). The DWP, which is integrated within the Samsung Health service, is a 12-week health and wellness program designed to help adults with type 2 diabetes achieve a healthy lifestyle and to help manage their condition. More information
on DWP is available at: www.welldoc.com/diabeteswellness
Welldoc® is a leading digital therapeutic company revolutionizing chronic disease management to help transform lives. Our groundbreaking technology is guiding individuals through the complicated journey of living with chronic diseases, with a goal of helping individuals self-manage their conditions to achieve significant clinical outcomes and cost savings. We began our journey by mastering diabetes management solutions and are moving rapidly into creating additional tools for managing other chronic diseases including hypertension, chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF). We are the first digital health company based on a life science business model with a foundation that is built on randomized clinical trials that demonstrate significant clinical outcomes. We have taken an aggressive and innovative approach that utilizes sophisticated logic, precise algorithms, and artificial intelligence (AI), which integrates the most advanced mobile technology and behavioral insights. Welldoc partners with, collaborates with, and is backed by top healthcare companies (including Merck and Johnson and Johnson), leading innovators, dedicated investors, and top mobile technology companies (such as Samsung).